Log in
Log in
E-mail
Password

Show password
Remember
Forgot password ?
Become a member for free
Sign up
Become a member for free
Sign up
New member
Sign up for FREE
New customer
Discover our services
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Vertex Pharmaceuticals
  6. Summary
    VRTX   US92532F1003

VERTEX PHARMACEUTICALS

(VRTX)
  Report
Delayed Nasdaq  -  05/20 04:00:00 pm EDT
258.59 USD   +1.23%
05/19Vertex Pharmaceuticals - Suketu Upadhyay Elected to Vertex Board of Directors
AQ
05/18VERTEX PHARMACEUTICALS INC / MA : Submission of Matters to a Vote of Security Holders (form 8-K)
AQ
05/18Suketu Upadhyay Elected to Vertex Board of Directors
BU
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
05/16/2022 05/17/2022 05/18/2022 05/19/2022 05/20/2022 Date
254.17(c) 261.84(c) 252.35(c) 255.45(c) 258.59(c) Last
1 558 246 1 566 842 1 396 975 1 448 836 1 552 342 Volume
+3.02% +3.02% -3.62% +1.23% +1.23% Change
More quotes
Estimated financial data (e) (USD)
Sales 2022 8 585 M - -
Net income 2022 3 253 M - -
Net cash position 2022 10 823 M - -
P/E ratio 2022 20,5x
Yield 2022 -
Sales 2023 9 226 M - -
Net income 2023 3 558 M - -
Net cash position 2023 14 777 M - -
P/E ratio 2023 18,7x
Yield 2023 -
Capitalization 66 136 M 66 136 M -
EV / Sales 2022 6,44x
EV / Sales 2023 5,57x
Nbr of Employees 3 900
Free-Float 99,6%
More Financials
Company
Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases. Net sales break down by type of income as follows: - income from sales of products (99.9%); - royalties and income from partnership, research, and development agreements (0.1%). Net sales are distributed... 
Read more
More about the company
Ratings of Vertex Pharmaceuticals
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
B
More Ratings
All news about VERTEX PHARMACEUTICALS
05/19Vertex Pharmaceuticals - Suketu Upadhyay Elected to Vertex Board of Directors
AQ
05/18VERTEX PHARMACEUTICALS INC / MA : Submission of Matters to a Vote of Security Holders (for..
AQ
05/18Suketu Upadhyay Elected to Vertex Board of Directors
BU
05/18Vertex Pharmaceuticals Incorporated Elects Suketu Upadhyay as Independent Director
CI
05/17Vertex Pharmaceuticals Pledges $50 Million to Health Equity
MT
05/17Vertex Announces Further Expansion in the Boston Seaport at Dedication of the Jeffrey L..
BU
05/17Vertex Pharmaceuticals Incorporated Announces Further Expansion in the Boston Seaport A..
CI
05/17Vertex Announces $50 Million Commitment to Health Equity With Three Initial Grants
BU
05/09UBS Adjusts Vertex Pharmaceuticals Price Target to $321 From $322, Maintains Buy Rating
MT
05/06VERTEX PHARMACEUTICALS INC / MA Management's Discussion and Analysis of Financial Cond..
AQ
05/06Goldman Sachs Adjusts Price Target for Vertex Pharmaceuticals to $368 From $329, Mainta..
MT
05/06Wells Fargo Adjusts Vertex Pharmaceuticals' Price Target to $305 From $300, Reiterates ..
MT
05/06Baird Downgrades Vertex Pharmaceuticals to Neutral From Outperform, Adjusts Price Targe..
MT
05/06RBC Capital Adjusts Price Target on Vertex Pharmaceuticals to $267 From $274, Keeps Sec..
MT
05/06Piper Sandler Adjusts Price Target on Vertex Pharmaceuticals to $242 From $249, Maintai..
MT
More news
News in other languages on VERTEX PHARMACEUTICALS
05/18Vertex Pharmaceuticals Incorporated élit Suketu Upadhyay comme administrateur indépenda..
05/17Vertex Pharmaceuticals s'engage à verser 50 millions de dollars pour l'équité en santé
05/17Vertex Pharmaceuticals Incorporated annonce une nouvelle expansion dans le port maritim..
05/05Earnings Flash (VRTX) VERTEX PHARMACEUTICALS INCORPORATED annonce des revenus de 2,1 mi..
05/05Hausse des résultats de Vertex Pharmaceuticals au premier trimestre ; réaffirmation des..
More news
Analyst Recommendations on VERTEX PHARMACEUTICALS
More recommendations
Analysis
PUMP / DUMP #13 : This week's gainers and losers
Chart VERTEX PHARMACEUTICALS
Duration : Period :
Vertex Pharmaceuticals Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends VERTEX PHARMACEUTICALS
Short TermMid-TermLong Term
TrendsBearishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 26
Last Close Price 258,59 $
Average target price 294,18 $
Spread / Average Target 13,8%
EPS Revisions
Managers and Directors
Reshma Kewalramani President, Chief Executive Officer & Director
Charles F. Wagner Chief Financial Officer & Executive Vice President
Jeffrey M. Leiden Executive Chairman
David Matthew Altshuler Chief Scientific Officer & EVP-Global Research
Carmen Bozic Chief Medical Officer & EVP-Medical Affairs
Sector and Competitors
1st jan.Capi. (M$)
VERTEX PHARMACEUTICALS17.76%66 136
GILEAD SCIENCES, INC.-12.08%80 075
REGENERON PHARMACEUTICALS, INC.4.69%71 235
WUXI APPTEC CO., LTD.-16.92%42 735
BIONTECH SE-36.77%39 612
GENMAB A/S-17.26%20 205